Live webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...
Oxford, UK – 16 July 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has signed an agreement with Plowshare Therapies ("Plowshare"), a ...
- Up to $125 million Oaktree loan facility to support OXB's global CDMO operations and growth strategy - $60 million upfront to repay existing $50 million loan facility and for general corporate ...
OXB (formerly Oxford BioMedica), a listed gene and cell therapy firm, is anticipating strong growth in its latest half-year trading update. The company expects to report revenues of between £70m and ...
Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK - 23 June 2025: OXB (LSE: OXB) ("the Company”), a global ...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...
Live webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results